Signacor Therapeutics secures £1.1m for heart disease treatment development

Cardiaza, a patented epigenetic modifying therapy designed to treat symptomatic hypertrophic cardiomyopathy, is the primary focus of Belfast-based Signacor Therapeutics Limited following its latest funding round. The clinical-stage biotechnology company has raised an estimated £1.1m to advance its work in reversing heart damage and preventing further deterioration in patients with the condition.

Founded in 2024, Signacor Therapeutics targets the underlying pathology of heart disease to provide first-in-class therapies. The company operates with a small team, reporting four employees in its latest financial accounts for the year ended 30 June 2025. This recent capital injection follows an allotment of shares in April 2026, with formal documentation filed in May.

The company recently expanded its board with the appointment of Dr. Natalie Pankova as a director in April. Unverified LinkedIn data suggests Dr. Pankova may be a venture capital pre-seed investor and a leader in healthcare technology and innovation.

Signacor Therapeutics focuses on addressing heart conditions that currently have limited treatment options. By utilizing epigenetic modification, the company aims to address the root causes of hypertrophic cardiomyopathy rather than solely managing patient symptoms. The £1.1m round provides additional resources for the clinical-stage firm as it continues the development and testing of its lead product.